Global Gastric Cancer Drugs Market by Molecule Type (Biologics, Small Molecules), Lines of Chemotherapy (First-line Chemotherapy, Second-line Chemotherapy), Route of Administration - Forecast 2024-2030- Product Image

Sale

Global Gastric Cancer Drugs Market by Molecule Type (Biologics, Small Molecules), Lines of Chemotherapy (First-line Chemotherapy, Second-line Chemotherapy), Route of Administration - Forecast 2024-2030

Report
195 Pages
March 2024
Region: Global
360iResearch™
ID: 4904412

UP TO €844EUR$875USD£724GBP OFF until Dec 31^st 2024

The Gastric Cancer Drugs Market size was estimated at USD 3.83 billion in 2023, USD 4.06 billion in 2024, and is expected to grow at a CAGR of 6.14% to reach USD 5.81 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gastric Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gastric Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gastric Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., ASLAN Pharmaceuticals Pte Ltd, AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., SELLAS Life Sciences Group, Inc., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Gastric Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Molecule Type
- Biologics
- Small Molecules
Lines of Chemotherapy
- First-line Chemotherapy
- Second-line Chemotherapy
Route of Administration
- Oral
- Parenteral

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Gastric Cancer Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gastric Cancer Drugs Market?
What are the technology trends and regulatory frameworks in the Gastric Cancer Drugs Market?
What is the market share of the leading vendors in the Gastric Cancer Drugs Market?
Which modes and strategic moves are suitable for entering the Gastric Cancer Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Gastric Cancer Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
5.1.1.2. Introduction of novel therapies for metastatic stomach cancer
5.1.1.3. Increase in awareness about the symptoms and causes of gastric cancer
5.1.2. Restraints
5.1.2.1. Stringent regulations and policies for approval of the drugs
5.1.3. Opportunities
5.1.3.1. Accelerating research and development activities in the drugs for gastic cancer
5.1.3.2. Rapid adoption of biosimilars in oncology
5.1.4. Challenges
5.1.4.1. Availability of the counterfeit drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Gastric Cancer Drugs Market, by Molecule Type

6.1. Introduction
6.2. Biologics
6.3. Small Molecules

7. Gastric Cancer Drugs Market, by Lines of Chemotherapy

7.1. Introduction
7.2. First-line Chemotherapy
7.3. Second-line Chemotherapy

8. Gastric Cancer Drugs Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Americas Gastric Cancer Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Gastric Cancer Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Gastric Cancer Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Amgen Inc.
13.1.2. ASLAN Pharmaceuticals Pte Ltd
13.1.3. AstraZeneca PLC
13.1.4. Bayer AG
13.1.5. Bristol Myers Squibb Company
13.1.6. Eli Lilly and Company
13.1.7. F. Hoffmann-La Roche AG
13.1.8. GlaxoSmithKline PLC
13.1.9. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
13.1.10. Merck & Co., Inc.
13.1.11. Novartis AG
13.1.12. Pfizer Inc.
13.1.13. SELLAS Life Sciences Group, Inc.
13.1.14. Taiho Pharmaceutical Co., Ltd.
13.1.15. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. GASTRIC CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GASTRIC CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GASTRIC CANCER DRUGS MARKET DYNAMICS
FIGURE 7. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
FIGURE 8. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2030 (%)
FIGURE 10. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. GASTRIC CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 6. GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 9. GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 25. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 26. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 28. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 29. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 42. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 43. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 45. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 46. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 51. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 52. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 69. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 79. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 80. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 82. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 83. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 85. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 88. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 92. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 97. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 98. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 106. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 107. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 109. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 112. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 113. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 124. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 125. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 133. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 134. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 142. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 143. GASTRIC CANCER DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Amgen Inc.
ASLAN Pharmaceuticals Pte Ltd
AstraZeneca PLC
Bayer AG
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
SELLAS Life Sciences Group, Inc.
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	195
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 4.06 Billion
Forecasted Market Value ( USD ) by 2030	$ 5.81 Billion
Compound Annual Growth Rate	6.1%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3257EUR$3,374USD£2,794GBP €3619EUR$3,749USD£3,104GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4125EUR$4,274USD£3,539GBP €4584EUR$4,749USD£3,932GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4994EUR$5,174USD£4,284GBP €5549EUR$5,749USD£4,760GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5863EUR$6,074USD£5,029GBP €6514EUR$6,749USD£5,588GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7600EUR$7,874USD£6,519GBP €8445EUR$8,749USD£7,244GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Gastric Cancer Drugs Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

Global Gastric Cancer Market Size, Share & Industry Trends Analysis Report By Route of Administration (Injectable and Oral), By Treatment Type, By Disease Type, By Distribution Channel, By Drug Class, By Regional Outlook and Forecast, 2023-2029

Gastric Cancer Drugs Global Market Report 2024

Gastric Cancer - Pipeline Insight, 2024

HER2-positive Gastric Cancer - Pipeline Insight, 2024